{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:21:21Z","timestamp":1767140481165,"version":"build-2238731810"},"update-to":[{"DOI":"10.1007\/s00296-011-2247-6","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"record-id":"2351"}],"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T00:00:00Z","timestamp":1321660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00296-011-2247-6","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T00:55:11Z","timestamp":1321577711000},"page":"1041-1041","source":"Crossref","is-referenced-by-count":0,"title":["RETRACTED ARTICLE: Ten-year survival rates of methylprednisolone plus cyclophosphamide followed by mycophenolate mophetyl of azathiopurine for progressive systemic sclerosis patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Metin","family":"Isik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Akdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Agit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"K\u0131l\u0131n\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"\u00c7alg\u00fcneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,19]]},"reference":[{"key":"2247_CR1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthr Rheum 44:1351\u20131358","journal-title":"Arthr Rheum"},{"key":"2247_CR2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","volume":"44","author":"AE Thompson","year":"2001","unstructured":"Thompson AE, Shea B, Welch V, Fenlon D, Pope JE (2001) Calcium-channel blockers for Raynaud\u2019s phenomenon in systemic sclerosis. Arthr Rheum 44:1841\u20131847","journal-title":"Arthr Rheum"},{"key":"2247_CR3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"21","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 21:425\u2013434","journal-title":"Ann Intern Med"},{"key":"2247_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","volume":"132","author":"H Olschewski","year":"2000","unstructured":"Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM et al (2000) Inhaled Iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH study group. Ann Intern Med 132:435\u2013443","journal-title":"Ann Intern Med"},{"key":"2247_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1054\/plef.2002.0380","volume":"67","author":"Y Matsukawa","year":"2002","unstructured":"Matsukawa Y, Saito O, Aoki M, Abe M, Nishinarita S, Sawada S et al (2002) Long-term administration of beraprost, an oral prostacyclin analogue, improves pulmonary diffusion capacity in patients with systemic sclerosis. Prostaglandins Leukot Essent Fatty Acids 67:45\u201349","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2247_CR6","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","volume":"48","author":"MD Mayes","year":"2003","unstructured":"Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthr Rheum 48:2246\u20132255","journal-title":"Arthr Rheum"},{"key":"2247_CR7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/rheumatology\/39.8.865","volume":"39","author":"SJ Morton","year":"2000","unstructured":"Morton SJ, Powell RJ (2000) Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology 39:865\u2013869","journal-title":"Rheumatology"},{"key":"2247_CR8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jacc.2004.02.036","volume":"43","author":"DB Badesch","year":"2004","unstructured":"Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O et al (2004) Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43:56\u201361","journal-title":"J Am Coll Cardiol"},{"key":"2247_CR9","doi-asserted-by":"crossref","unstructured":"Sitbon O, Humbert M et al (2002) Nuner H. Intravenous infusion of epoprostanol in severe pulmonary hypertension: long term survival and prognostic factors. J Am Coll Cardiol 40:770\u2013778","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"2247_CR10","unstructured":"Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G et al (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst 2:cd000953"},{"key":"2247_CR11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","volume":"126","author":"RJ Oudiz","year":"2004","unstructured":"Oudiz RJ, Schilz RJ, Barst RJ, Galie N, Rich S, Rubin LJ et al (2004) Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126:420\u2013427","journal-title":"Chest"},{"key":"2247_CR12","first-page":"1064","volume":"35","author":"A Berezne","year":"2008","unstructured":"Berezne A, Ranque B, Valeyre D et al (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35:1064\u20131072","journal-title":"J Rheumatol"},{"key":"2247_CR13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ et al (2008) Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomised controlled trials and observational prospective cohort studies. Arthr Res Ther 10:124\u2013132","journal-title":"Arthr Res Ther"},{"key":"2247_CR14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0272989X08317015","volume":"28","author":"D Khanna","year":"2008","unstructured":"Khanna D, Furst DE, Clements PJ et al (2008) Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Mak 28:926\u2013937","journal-title":"Med Decis Mak"},{"key":"2247_CR15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/ard.57.11.682","volume":"57","author":"R Hesselstrand","year":"1998","unstructured":"Hesselstrand R, Scheja A, \u00c5kesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:682\u2013686","journal-title":"Ann Rheum Dis"},{"key":"2247_CR16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"AJ Gerbino","year":"2008","unstructured":"Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455\u2013460","journal-title":"Chest"},{"key":"2247_CR17","first-page":"613","volume":"25","author":"C Paone","year":"2007","unstructured":"Paone C, Chiarolanza I, Cuomo G et al (2007) Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low-dose cyclophosphamide pulse therapy. Clin Exp Heumatol 25:613\u2013616","journal-title":"Clin Exp Heumatol"},{"key":"2247_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","volume":"25","author":"O Nadaskevich","year":"2006","unstructured":"Nadaskevich O, Davis P, Fritzler M et al (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic clerosis. Clin Rheumatol 25:205\u2013212","journal-title":"Clin Rheumatol"},{"key":"2247_CR19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10067-004-0906-7","volume":"23","author":"K Dheda","year":"2004","unstructured":"Dheda K, Lalloo UG, Cassim B, Mody GM (2004) Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 23:306\u2013309","journal-title":"Clin Rheumatol"}],"updated-by":[{"DOI":"10.1007\/s00296-011-2247-6","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"record-id":"2351"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2247-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-011-2247-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-011-2247-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T02:12:39Z","timestamp":1686449559000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-011-2247-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,19]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2247"],"URL":"https:\/\/doi.org\/10.1007\/s00296-011-2247-6","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,19]]}}}